TTrialPathMatch Me to Trials
← Back to trials
RecruitingHIV -1 Infection

Study of GS-0415 and How It Works in People With HIV

Eligible age

18–65 yrs

Accepts

All genders

Locations

11 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and intravenous (IV) GS-0415 in people with HIV-1 (PWH) on antiretroviral treatment. The primary objectives of this study are to evaluate the safety and tolerability of escalating, single and multiple subcutaneous (SC) and intravenous (IV) doses of GS-0415, administered in PWH who are virologically suppressed on antiretroviral therapy (ART) and to evaluate the pharmacokinetics (PK) of GS-0415.

Sponsor: Gilead Sciences

Where it's recruiting

California

Los Angeles

District of Columbia

Washington D.C.

Florida

Miami Lakes · West Palm Beach

Georgia

Atlanta · Columbus

Indiana

Indianapolis

Nevada

Las Vegas

New York

The Bronx

North Carolina

Durham · Winston-Salem

Ohio

Cincinnati · Columbus

Source: ClinicalTrials.gov · NCT07719491 · last updated 2026-09-23

Study of GS-0415 and How It Works in People With HIV · TrialPath